Sublime Culture Inc Facility in Final Stages of ACMPR Licensing
Vancouver, British Columbia, Canada / TheNewswire / March 28th, 2017 - MYM Nutraceuticals Inc. (CSE:MYM) (OTC:MYMMF) (FRA:OMY), (the "Company" or "MYM") is pleased to announce that it has signed an agreement with TheraCann International Benchmark Corporation ("TheraCann"), a leading cannabis consultancy for assistance in preparing for Health Canada's pre-license inspection of Sublime Culture Inc. facility, (MYM owns a 51% majority share of Sublime Culture Inc.).
TheraCann, offers a one-stop, full-service solution for the International cannabis marketplace, including regulatory applications, planning, facility design, cultivation, analytics, systems integration, marketing and communications, TheraCann provides cannabis-related businesses with solutions to fit their regulatory and business requirements.
Brent McNiven, President of, TheraCann Canada commented: "Our team is excited to work with MYM and Sublime to cross these final hurdles and get them to market. We have extensive experience in helping ACMPR (Access to Cannabis for Medical Purposes Regulations) clients pass inspection and get their operations running at full capacity, quicker and more efficiently. Our proprietary systems, equipment and processes have been successfully implemented to get our clients licensed in facilities in both the US and Canada."
Jonathan Fiteni, MYM CEO, commented: "Our commitment to a successful application is unwavering. We will do absolutely what ever it takes to ensure success. Bringing on an experienced team to help move us through the critical last stages of the ACMPR process is part of our plan to help secure that success. TheraCann offers one of the best support teams when it comes to testing and laboratory analysis, something we feel is vital to our future success. With critical planning ahead for additional licensing and expansion, I believe we have secured the right team to guide us through the complexities of a highly regulated industry."
Sublime Culture Inc. Facility update: The Sublime Culture Inc. ("Sublime") project is currently finalizing some additional construction updates and awaiting approval on minor facility layout changes needed for occupation compliance. Negotiations have begun to occupy the remaining space in the building, which would allow sublime and their engineers to prepare building plans for expansion, a full 7 months ahead of schedule. Sublime will be adding an additional 10,000 sq. ft. of grow canopy and extraction space to meet projected demand. Sublime expects to be ready for Health Canada pre-license inspection by September, 2017 with operations coming online later this year.
MYM Nutraceuticals Inc. (CSE:MYM)(OTC:MYMMS)(FRA:OMY) is a public company trading on the Canadian Stock Exchange whose primary focus is developing high-end organic medicinal marijuana supplements and topical products. MYM also has an interest in the development of high-density farming facilities and technologies that allow MYM to expand its brand into the global market.
ON BEHALF OF THE BOARD
CEO and Director
This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company's Management's Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on www.sedar.com.